The management of care for a pregnant woman with recurrent pregnancy losses and proven immunodeficiency from the obstetrician’s point of view
Authors:
Michal Koucký
Authors‘ workplace:
Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze
Published in:
Čas. Lék. čes. 2021; 160: 14-19
Category:
Review Article
Overview
Recurrent pregnancy losses represent sensitive issue not only for the couple, but also for all healthcare professionals involved. In a broader context, they include not only recurrent miscarriages, but also the issue of periviable preterm birth with subsequent neonatal death and unexplained fetal death. This area requires an interdisciplinary approach. The field of reproductive immunology best answers questions related to pregnancy complications. However, there is currently no accurate recommendation as to who should care for such women. In this article I summarize the current state of knowledge about the issue, current experience with care management, including case studies.
Keywords:
recurrent pregnancy loss – pregnancy – immunomodulation – Progesterone – low molecular weight heparin – immunoglobulin
Sources
- Bender Atik R, Christiansen OB, Elson J et al.; ESHRE Guideline Group on RPL. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open 2018; 2018(2): hoy004.
- Toth B, Würfel W, Bohlmann M et al. Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k‐Level, AWMF Registry Number 015/050). Geburtshilfe Frauenheilkd 2018; 78: 364–381.
- Royal College of Obstetricians & Gynaecologists. The investigation and treatment of couples with recurrent first‐trimester and second-trimester miscarriage. Green-top Guideline No. 17. RCOG, 2011. Dostupné na: www.rcog.org.uk/globalassets/documents/guidelines/gtg_17.pdf
- American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98: 1103–1111.
- Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93: 1234–1243.
- Kent DM, Steyerberg E, van Klaveren D. Personalized evidence-based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018; 363: k4245.
- Peyron R, Aubeny E, Targosz V et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328: 1509–1513.
- Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci 2011; 18(1): 6–19.
- Thomas P, Pang Y. Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells. Neuroendocrinology 2012; 96(2): 162–171.
- Arck P, Hansen PJ, Mulac Jericevic B et al. Progesterone during pregnancy: endocrine-immune cross talk in mammalian species and the role of stress. Am J Reprod Immunol 2007; 58: 268–279.
- Hickey DK, Patel MV, Fahey JV, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 2011; 88(2): 185–194.
- Miko E, Halasz M, Jericevic-Mulac B et al. Progesterone-induced blocking factor (PIBF) and trophoblast invasiveness. J Reprod Immunol 2011; 90(1): 50–57.
- Szekeres-Bartho J, Polgar B. PIBF: the double-edged sword. Pregnancy and tumor. Am J Reprod Immunol 2010; 64(2): 77–86.
- Hudić I, Stray-Pedersen B, Szekeres-Bartho J et al. Maternal serum progesterone-induced blocking factor (PIBF) in the prediction of preterm birth. J Reprod Immunol 2015; 109: 36–40.
- Areia A, Vale-Pereira S, Alves V et al. Membrane progesterone receptors in human regulatory T cells: a reality in pregnancy. BJOG 2015 Oct;122(11): 1544–1550.
- Areia A, Vale-Pereira S, Alves V et al. Can membrane progesterone receptor α on T regulatory cells explain the ensuing human labour? J Reprod Immunol 2016; 113: 22–26.
- Dressing GE, Goldberg JE, Charles NJ et al. Membrane progesterone receptor expression in mammalian tissues: a review of regulation and physiological implications. Steroids 2011; 76(1–2): 11–17.
- Dodd JM, Jones L, Flenady V et al. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013; (7): CD004947.
- Hassan SS, Romero R, Vidyadhari D et al. PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38(1): 18–31.
- Romero R, Conde-Agudelo A, Da Fonseca E et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 2018; 218(2): 161–180.
- Kacerovský M, Kokrdová Z, Koucký M et al. Spontánní předčasný porod. Doporučený postup ČGPS ČLS JEP. Česká Gynekologie 2017; 82(2): 160–165.
- Labarta E, Rodríguez C. Progesterone use in assisted reproductive technology. Best Pract Res Clin Obstet Gynaecol 2020; 69: 74–84.
- Coomarasamy A, Devall AJ, Cheed V et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Engl J Med 2019; 380(19): 1815–1824.
- Saccone G, Schoen C, Franasiak JM et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril 2017; 107(2): 430–438.e3.
- Devall AJ, Coomarasamy A. Sporadic pregnancy loss and recurrent miscarriage. Best Pract Res Clin Obstet Gynaecol 2020; 69: 30–39.
- Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl.): 64S–94S.
- Dodd JM, McLeod A, Windrim RC et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 24: CD006780.
- Neykova K, Dimitrova V, Dimitrov R. The effect of antithrombotic therapy on the recurrence of placenta-mediated diseases in pregnancy. J Matern Fetal Neonatal Med 2020: 1–7, doi: 10.1080/14767058.2020.1757065.
- Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012; 67(4): 296–304.
- Carp H. Immunotherapy for recurrent pregnancy loss. Best Pract Res Clin Obstet Gynaecol 2019; 60: 77–86.
- Jafarzadeh S, Ahmadi M, Dolati S et al. Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function. J Cell Biochem 2019; 120(4): 5424–5434.
- Plaçais L, Kolanska K, Kraiem YB et al. Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review. Eur J Obstet Gynecol Reprod Biol 2020; 252: 100–104.
- Martini AE, Jasulaitis S, Fogg LF et al. Evaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure. J Hum Reprod Sci 2018; 11(3): 261–268.
- Balan A, Szaingurten-Solodkin I, Swissa SS et al. The effects of pravastatin on the normal human placenta: lessons from ex-vivo models. PLoS One 2017; 12(2): e0172174.
- Chaiworapongsa T, Romero R, Korzeniewski SJ et al. Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD). J Matern Fetal Neonatal Med 2016; 29(6): 855–862.
- Tong S, Kaitu'u-Lino TJ, Hastie R et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol 2020; S0002-9378(20)31071-1, doi: 10.1016/j.ajog.2020.09.014.
- Lefkou E, Varoudi K, Pombo J et al. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. Biochem Pharmacol 2020; 182: 114217.
- Haider BA, Bhutta ZA. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev 2017; 4(4): CD004905.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
2021 Issue 1
Most read in this issue
- Circulating NK and NKT cells in the diagnosis and treatment of immunological causes of female infertility – retrospective data analysis from the tertiary clinical center
- Current possibilities of diagnostics and treatment of immunological causes of female infertility
- Diagnostics of infertile males in the 21st century – a traditional concept or a modern approach?
- Conspiracy theories as a natural part of pandemics